10-K - KNOW LABS, INC. (0001074828) (Filer)

8-K - KNOW LABS, INC. (0001074828) (Filer)

8-K - KNOW LABS, INC. (0001074828) (Filer)

8-K/A - KNOW LABS, INC. (0001074828) (Filer)

DEF 14A - KNOW LABS, INC. (0001074828) (Filer)

8-K - KNOW LABS, INC. (0001074828) (Filer)

8-K - KNOW LABS, INC. (0001074828) (Filer)

PRE 14A - KNOW LABS, INC. (0001074828) (Filer)

8-K - KNOW LABS, INC. (0001074828) (Filer)

8-K - KNOW LABS, INC. (0001074828) (Filer)

Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter ended June 30, 2023. Financial Highlights: Know Labs reported a net loss of $3.59 million dollars in the third quarter of 2023, compared to a net loss of $3.03 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.07, unchanged from the year ago period of a loss of $0.07 before preferred stock dividends. Recorded a non-cash charge to earnings of $4.96 million related to the fair market value of dividends on the Company's Series C and D preferred stock, that were either paid or accrued in share

Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the second quarter ended March 31, 2023. Financial Highlights: Know Labs reported a net loss of $4.93 million dollars in the second quarter of 2023, compared to a net loss of $6.14 million dollars in the year-ago period, which translates to Earnings Per Share of a loss of $0.10, an improvement over the year ago period of a loss of $0.16. Research and development expense for the second quarter was $2.56 million dollars as compared to $1.25 million dollars in 2022. The increase in R&D expense was related to staff increases in engineering, third party te

Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the first quarter ended December 31, 2022. Financial Highlights: Know Labs reported a net loss of $3.82 million in the first quarter of 2023, compared to a net loss of $5.36 million in the first quarter of 2022, which translates to Earnings Per Share of a loss of $0.08 versus a loss of $0.15 in the year ago period. Research and development expense for the first quarter ended December 31, 2022, was $1.74 million as compared to $886,000 in the same year ago period. The increase in R&D expense was related to staff increases in engineering, third party techn

SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)

SC 13D - KNOW LABS, INC. (0001074828) (Subject)

SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)

SC 13G - KNOW LABS, INC. (0001074828) (Subject)

SC 13D/A - KNOW LABS, INC. (0001074828) (Subject)

SC 13G/A - KNOW LABS, INC. (0001074828) (Subject)

Somogyi to lead Know Labs' "Skunkworks" Program and drive global revenues. Know Labs, Inc. (NYSE:KNW), an emerging leader in non-invasive medical diagnostic technology, today announced the appointment of Chris Somogyi as President, International. With over 40 years of experience in commercializing innovation across related industries, Somogyi brings a wealth of expertise to lead the Company's "Skunkworks" Program and global patent licensing efforts. In his role, Somogyi will focus on identifying new applications of Know Labs' extensive intellectual property (IP) portfolio consisting of over 300 patents issued, pending and in-process and covering more than 100 medical and non-medical app

New Members Bring Extensive Clinical Diabetes Management and FDA Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of four new members to the Company's Medical and Scientific Advisory Board. The new additions to the Advisory Board are Jeff Hitchcock, Karmeen Kulkarni, Dr. Meng Tan and Dr. Satish Garg. They bring to the board extensive experience in clinical diabetes management, including the advancement of new technologies and innovation in medical diagnostics. The Medical and Scientific Advisory Board is chaired by Know Labs' Chief Medical Officer, Dr. James H. "Andy" Anderson. The Advisory Board p

Appoints Three New Directors with Deep Sector Expertise Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the appointment of three new members to the Company's Board of Directors. These appointments increase the number of Directors to seven. Each new Director brings to the board extensive sector-relevant experience with deep knowledge of the science and the marketplace that is the focus of Know Labs. The new appointees are John Cronin, Larry Ellingson and Tim Londergan. John Cronin is the founder and CEO of ipCapital Group, Inc., a leading global advisory company on intellectual property strategy and monetization. Cronin beg

Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the establishment of a Scientific Advisory Board (SAB) comprised of distinguished researchers, innovators and experts in medical technology and human health. SAB members will advise the company and its strategic partners on advancing the company's progress in algorithm refinement, device development, clinical trial design and research publication strategy. SAB members will be working alongside Know Labs' current Medical and Regulatory Advisory Board members who have been supporting the team since 2020 and will be pivotal in helping Know Labs accelerate the development and deliver

4/A - KNOW LABS, INC. (0001074828) (Issuer)

4 - KNOW LABS, INC. (0001074828) (Issuer)

4 - KNOW LABS, INC. (0001074828) (Issuer)

4 - KNOW LABS, INC. (0001074828) (Issuer)

4 - KNOW LABS, INC. (0001074828) (Issuer)

4 - KNOW LABS, INC. (0001074828) (Issuer)

4 - KNOW LABS, INC. (0001074828) (Issuer)

4 - KNOW LABS, INC. (0001074828) (Issuer)

4 - KNOW LABS, INC. (0001074828) (Issuer)

4 - KNOW LABS, INC. (0001074828) (Issuer)

The Company Responds to Shareholder Concerns and Reiterates Progress and Future Plans Know Labs, Inc. (NYSE:KNW), a leading developer of non-invasive diagnostics technology released this morning an overview of its Form 10-K annual report for its fiscal year ending September 30, 2024, and provided reassurance regarding its progress over the past year, its plans and the state of its financial stability in light of its auditor required going concern opinion. Know Labs (the "Company") issued a press release on November 15, 2024, regarding the receipt of an audit opinion with a going concern explanation from its independent registered public accounting firm. The filing of that press release

Know Labs, Inc. (NYSE:KNW), leading developer of non-invasive diagnostics technology, today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended September 30, 2024, which was filed on November 14, 2024 with the Securities and Exchange Commission, the audited financial statements contained an audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company's ability to continue as a going concern. See further discussion in Note 2 to the Company's financial statements included in the Company's Annual Report on Form 10-K. This announcement is made pursuant to NYSE American LLC Company Guid

Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today reported financial results for the fourth quarter and fiscal year ended September 30, 2024. Financial Highlights: Know Labs reported a net loss of $16.58 million dollars in FY2024, compared to a net loss of $15.29 million dollars in FY2023, an increase in net loss of 8.4%. This translates to Earnings Per Share of a loss of $0.20, better than FY2023 Earnings Per Share Loss of $0.41, an improvement of 51%, before preferred stock dividends. In FY2024, recorded a non-cash charge to earnings of $4.93 million, compared to $4.77 million FY2023. The non-cash items include (i) depreciation

Acceleration of Platform Development to Secure Multiple Strategic Partnerships Know Labs, Inc. (NYSE:KNW), a leading developer of non-invasive diagnostics technology, announced today two additions to its executive leadership team. The new executives are John Cronin and Dominic Klyve, Ph.D. They are tasked with both furthering the development of the Company's non-invasive diagnostic technology platform and building relationships with potential strategic partners. "John and Dominic bring extensive technology leadership and research experience to the Know Labs team," said Ron Erickson, CEO. "In their new roles they provide intellectual leadership to both drive our technology development and

Know Labs Retains the Stanbridge Group to Secure Automotive Joint Venture Partnerships Know Labs, Inc. (NYSE:KNW), a leading developer of non-invasive sensor technology, announced today that it has retained The Stanbridge Group to secure a strategic relationship with an automotive original equipment manufacturer to embed the Know Labs sensor technology in automobile steering wheels. In early preliminary tests, the Know Labs sensor demonstrated, in a laboratory setting, that it can non-invasively determine blood alcohol levels and the Company believes, in an automobile steering wheel, could prohibit an impaired individual from driving. This discovery occurred during the early development o

A Plan for Compliance and Activities to Increase Know Labs Valuation have been Undertaken Know Labs, Inc. (NYSE:KNW) (the "Company" or "Know Labs"), a leading developer of non-invasive diagnostics technology, announced today that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated September 27, 2024, notifying the Company that it is no longer in compliance with NYSE American continued listing standards. Specifically, the letter states that the Company is not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the "Company Guide"). Section 1003(a)(ii) requires a liste

Peer-reviewed journal publication validates the novelty of Know Labs' proprietary radiofrequency (RF) dielectric sensor and its application for non-invasive blood glucose monitoring Know Labs, Inc. (NYSE:KNW), a leading developer of non-invasive medical diagnostic technology, today announced the publication of its peer-reviewed study in IEEE Sensors Journal titled, "Non-Invasive Blood Glucose Measurement Using RF Spectroscopy and a lightGBM AI Model." IEEE Sensors is the leading scientific journal in the U.S. that focuses on the theory, design, fabrication and applications of sensing devices, with an emphasis on emerging sensor innovations. The article details historical developments and

Know Labs, Inc. (NYSE:KNW) (the "Company"), a leading developer of non-invasive medical diagnostic technology, today announced that it has entered into definitive agreements with certain investors to purchase 6,365,385 Units for an aggregate offering of $1.655 million at a public offering price of $0.26 per unit, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock at an initial exercise price of $0.26 (the "Offering"). The aggregate gross proceeds from the Offering will total $1.655 million before deducting estimated Offering expenses payable by Know Labs. The Offering closed on August 15, 2024. The Company intends to use th

Know Labs, Inc. (NYSE:KNW), a leading developer of non-invasive medical diagnostic technology, today reported financial results for the third quarter of the fiscal year 2024 ended June 30, 2024. Financial Highlights: In Q3 FY 2024, Know Labs reported a net loss of $4.10 million dollars, compared to a net loss of $3.60 million dollars in Q3 FY 2023, an increase in net loss of 13.9%. This translates to earnings per share of a loss of $0.05, better than the prior year earnings per share loss of $0.07, before preferred stock dividends. Recorded a non-cash charge to earnings of $1.58 million dollars principally related to stock-based compensation of $1.0 million dollars, ​​amortization o

Know Labs, Inc. (NYSE:KNW), a leading developer of non-invasive medical diagnostics technology, today announced the successful closing of its previously announced underwritten public offering of 13,250,000 units at a public offering price of $0.26 per unit, with each unit consisting of one share of its common stock and one warrant to purchase one share of its common stock at an initial exercise price of $0.26, and the partial exercise of the underwriters' option to purchase 1,987,500 warrants (the "Offering"). The Company raised gross proceeds of $3.445 million less the underwriting discounts and commissions and estimated Offering expenses payable by Know Labs. The Offering was conducted

Research In Diabetes Technology & Therapeutics Journal Validates Proprietary RF Dielectric Sensor And ML Algorithms For Classifying Hyperglycemic, Normoglycemic, And Hypoglycemic States

Know Labs, Inc. (NYSE:KNW), a leading developer of non-invasive medical diagnostic technology, today announced the publication of its peer-reviewed study in Diabetes Technology & Therapeutics Journal titled, “A Glycemic Status Classification Model Using a Radiofrequency Noninvasive Blood Glucose Monitor.” Diabetes Technology & Therapeutics is a leading, peer-reviewed journal covering all aspects of diagnosing and managing diabetes with cutting-edge devices, drugs, drug delivery systems, and software. The published clinical research results demonstrate that Know Labs’ proprietary non-invasive radiofrequency (RF) dielectric sensor and trade-secret machine learning (ML) algorithms correctly cl

Benchmark analyst Bruce Jackson reiterates Know Labs (AMEX:KNW) with a Speculative Buy and maintains $1 price target.

Know Labs (AMEX:KNW) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 30 percent increase over losses of $(0.10) per share from the same period last year.

The Company's oral abstract presentation features results from its clinical study that demonstrate the accuracy and medical application of its proprietary sensor.

Benchmark analyst Bruce Jackson initiates coverage on Know Labs (AMEX:KNW) with a Speculative Buy rating and announces Price Target of $1.

Shares of NetApp, Inc. (NASDAQ:NTAP) shares rose sharply in today’s pre-market trading after the company reported better-than-expected third-quarter financial results and issued guidance. NetApp posted adjusted earnings of $1.94 per share, beating market estimates of $1.69 per share. The company’s quarterly sales came in at $1.610 billion, versus expectations of $1.591 billion, according to data from Benzinga Pro. NetApp shares jumped 17.3% to $104.50 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Nxu, Inc. (NASDAQ:NXU) gained 111.4% to $1.69 in pre-market trading after the company announced it successfully charged a Tesla Cybertruck on Feb. 26

Know Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has entered into a funding agreement for an investment of up to $12 million, of which it has executed a $4 million close (the "Funding Agreement") with Lind Global Fund II LP, an investment entity managed by The Lind Partners, a New York-based institutional fund manager (together, "Lind"). Ron Erickson, Chief Executive Officer and Chairman at Know Labs, commented, "This investment will enable Know Labs to accelerate development across our four core work streams including, hardware development, expanded data collection in clinical research, algorithm development, and expansion

The KnowU incorporates the sensor intended for FDA submissionKnow Labs, Inc. (NYSE:KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the KnowU™, its wearable non-invasive continuous glucose monitor (CGM). The Company announced its first prototype in June 2023. The KnowU is the result of an accelerated development process over the last eight months. The KnowU incorporates the sensor that the Company plans to submit to the FDA for clearance. This proprietary sensor has been tested and proven stable and accurate in the lab setting. It was included in the Company's prototype to validate stability outside of the lab, and is now miniaturized and wearable.Th